All In Biotech

Drug Trial Radar · NCT07200206

A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea

A Prospective, Single-arm, Non-interventional, Multi-center, Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

3,000

Planned (sponsor's estimate)

Start

Oct 2, 2025

Primary completion

Sep 26, 2029

Study completion Sep 26, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Oct 1, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 0 days, up to 24 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is conducted as part of the local risk management plan to collect and understand the following information about the surveillance drug under the real-world clinical practice settings. To evaluate the safety of Beyfortus in Korean children who received Beyfortus under the real-world clinical practice settings per the approved indication. The investigator will decide whether to enroll participants if they determine that administering Beyfortus according to current practice can provide clinical benefits in terms of safety and efficacy Participants will be followed-up for 180 days after Beyfortus administration.

Conditions

  • Respiratory Syncytial Virus

Interventions

  • NirsevimabBiological

    Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurence of Adverse Events (AEs)Time frame: Up to 180 days post dose
  2. Occurence of Serious Adverse Events (SAEs)Time frame: Up to 180 days post dose
  3. Occurrence of AE of special interest (AESI)Time frame: Up to 180 days post dose
  4. Occurence of Adverse Drug Reaction (ADRs) as Specified in Approved Local LabelTime frame: Up to 180 days post dose
  5. Occurrence of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI)Time frame: Up to 180 days post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 4100007

    Hwaseong-si, Gyeonggi-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.